Adapta With MVP
Pacing System
Adapta With MVP Pacing System

Adapta With MVP Pacing System

Adapta® with MVP Pacing System offers managed ventricular pacing, atrial therapy, ventricular capture, and remote cardiac telemetry.

Why Is It Critical to Pace Less?

Reducing unnecessary ventricular pacing has been shown to improve clinical outcomes by reducing the risks of atrial fibrillation (AF)1-4 and heart failure hospitalization (HFH).1,4

There is a 1% increase in the risk of AF for each 1% increase in cumulative right ventricular pacing.4

Important Safety Information

Changes in a patient's disease and/or medications may alter the efficacy of a device's programmed parameters or related features.

 Risk of Atrial Fibrillation

Risk of Atrial Fibrillation

RV pacing > 40% of the time in DDDR mode was associated with a 2.6-fold increased risk of HFH compared with pacing < 40%.4

Risk of Heart Failure Hospitalization

Risk of Heart Failure Hospitalization

References

  1. Anderson HR, Nielsen JC, Thomsen PEB, et al. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet. 1997;350:1210-1216.
  2. Skanes AC, Krahn AD, Yee R, et al, for the CTOPP Investigators. Progression to chronic atrial fibrillation after pacing: The Canadian Trial Of Physiologic Pacing. J Am Coll Cardiol. 2001;38:167-172.
  3. Neilsen J, Kristensen L, Andersen H, et al. A randomized comparison of atrial and dual chamber pacing in 177 consecutive patients with sick sinus syndrome. J Am Col Cardiol. 2003;42:614-623.
  4. Sweeney M, Hellkamp A, Ellenbogen K, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-2937.

How the Adapta Pacing System Works

Managed Ventricular Pacing Mode 

Managed Ventricular Pacing Mode

The new standard of care in pacing is to reduce unnecessary right ventricular pacing to as close to zero as possible. Mounting evidence suggests that right ventricular pacing is associated with a variety of detrimental effects, including risk of heart failure hospitalization and atrial fibrillation.1

Managed Ventricular Pacing

MVP® – Managed Ventricular Pacing provides the following benefits:2

  • Promotes intrinsic conduction 
  • Reduces unnecessary right ventricular pacing by 99%*3
  • Provides AAI(R) pacing with ventricular monitoring plus the safety of DDD(R) backup pacing when needed

Completely Automatic – Simple to Use

Atrial Capture Management and Ventricular Capture Management (ACM and VCM):

  • Provide complete long-term threshold management automatically 
  • Ensure pacing outputs remain at safe levels4

TherapyGuide™ – Tailored, Clinically-Oriented Programming Using Physician-Selected Parameters

  • Simplifies and tailors programming
  • Provides suggested device settings based on physician-selected patient conditions 

Quick Look II – All Key Information on One Screen 

  • Simplifies clinic follow-up with all key information on one screen 
  • Provides concise overview of patient, device, and lead status
  • Routine follow-up measurements are performed automatically 
  • All measurements are automatic and displayed upon initial interrogation

View details View details

Quick Look II on One Screen 

Detail - Quick Look II on One Screen

Cardiac Compass Trends

Concise information to:

  • Identify atrial arrhythmias
  • Make key therapy decisions (eg, titrating medications)
  • Monitor results of therapy changes

Assess Rhythm Control†

View details View details

Cardiac Compass Rhythm Control

Cardiac Compass® Rhythm Control

† Atrial Arrhythmia Trend of patient who received a change in antiarrhythmic drug therapy during an August follow-up. The change in medical therapy resulted in the decreased incidence and duration of AT/AF.

Assess Rate Control‡

View details View details

Rate histogram of ventricular beats during exercise-induced AT/AF

Rate histogram of ventricular beats occurring during exercise-induced AT/AF showing blocked conduction.

Rate Histogram of ventricular beats showing good conduction

Rate histogram of ventricular beats showing good conduction and rate control following change to patient's pharmacologic therapies for AT/AF.

‡The information collected may help with assessment of rate control and risk for stroke in patients with atrial tachyarrhythmias.

Medtronic CareLink Network for Pacemakers

Medtronic CareLink® Network, the leading Internet-based remote monitoring service, is now available for pacemakers.

* Median number

References

  1. Sweeney M, Hellkamp A, Ellenbogen K, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-2937. 2. Gillis A, Pürerfellner H, Israel C, et al. Reduction of unnecessary ventricular pacing due to the Managed Ventricular Pacing (MVP) mode in pacemaker patients: Benefit for both sinus node disease(SND) and AV block (AVB) indications. Heart Rhythm. 2005;Abstract AB21-1.
  2. EnRhythm Device Manual
  3. Gillis A, Pürerfellner H, Israel C, et al. Reduction of unnecessary ventricular pacing due to the Managed Ventricular Pacing (MVP) mode in pacemaker patients: Benefit for both sinus node disease (SND) and AV block (AVB) indications. Heart Rhythm. 2005;Abstract AB21-1.
  4. Ref Heart Rhythm, Vol. 2, No 11, November 2005

Specifications

Adapta DR with MVP

Mechanical
ModelSize (HxWxD mm)M (g)V (cc)ConnectorRadiopaque ID 
ADDR0144.7x47.9x7.527.112.1IS-1 BI or UNIPWB
ADDR0346.7x47.9x7.528.113.03.2 mm LP BI, IS-1or UNIPWB
ADDR0650.3x47.9x7.5 28.5 14.2 5 or 6 mm UNI* PWB 
ADDRS1
(small)
44.7x42.9x7.5 23.6 11.1IS-1 BI or UNIPWB 
ADDRL1
(longevity)
45.4x52.3x7.531.3 13.1 IS-1 BI or UNIPWB
* Parylene coating on backside of case
Battery
TypeLithium-iodine
Voltage2.8 V
Average Projected Capacity
Model ADDR01/03/061.2 Ah
Model ADDRS1.83 Ah
Model ADDRL11.4 Ah
Longevitywith MVP offwith MVP on
Model ADDR01/03/0611.3 years**12.4 years***
Model ADDRS18.5 years**9.4 years***
Model ADDRL114.0 years**15.4 years***
** DDDR or DDD, 60 ppm, 100% pacing, ventricle 2.0V," atrial 1.5V," 0.4 ms pulse width, 1000 Ω pacing impedance
*** MVP Mode ON – 50% atrial pacing and 5% ventricular pacing
Serial number begins with N

Adapta D with MVP

Mechanical
Model ID Size (HxWxD mm)M (g)V (cc)ConnectorRadiopaque ID
ADD0144.7x47.9x7.527.1 12.1 IS-1 BI or UNIPWB
Battery
TypeLithium-iodine
Voltage2.8 V
Average Projected Capacity1.2 Ah
Longevity
11.3 years*12.4 years** with MVP On
* DDD, 60 ppm, 100% pacing, ventricle 2.0V, " atrial 1.5V," 0.4 ms pulse width, 1000 Ω pacing impedance
** MVP Mode ON – 50% atrial pacing and 5% ventricular pacing
Serial number begins with N

Adapta VDD

Mechanical
ModelSize (HxWxD mm)M (g)V (cc) Connector Radiopaque ID 
 ADVDD01 44.7x42.9x7.523.6 11.1 IS-1 BI or UNI PWB 
Battery  
Type Lithium-iodine 
Voltage 2.8 V 
Average Projected Capacity .86 Ah 
Longevity
9.0 years* 
* YDD, 60 ppm, 100% pacing, 2.0 V, 0.4 ms pulse width, 1000
Ω pacing impedance
Nominal values indicated in bold
Serial number begins with N

Adapta SR

Mechanical
ModelSize (HxWxD mm)M (g)V (cc)ConnectorRadiopaque ID
ADSR0140.2x42.9x7.521.59.7IS-1 BI or UNIPWB
ADSR0342.9x42.9x7.522.510.53.2 mm LP BI, IS-1 BI or UNIPWB
ADSR0643.3x42.9x7.522.511.05 or 6 mm UNI*PWB
* Parylene coating on back side of case
Battery
TypeLithium-iodine
Voltage2.8 V
Average Projected Capacity Models ADSR01/03/06.86 Ah
Longevity
Models ADSR01/03/0610.0 years**
** SSIR or SSI, 60 ppm, 100% pacing, 2.0 V, 0.4 ms pulse width, 1000 Ω pacing impedance
Serial number begins with N

 

Last updated: 22 Sep 2010

Medtronic Manual Library

manuals-medtronic-com

Find instructions for use and product manuals.

More

Medtronic Connect

connect-thumb

Find presentations, animations, videos, photos, and other resources.

More

Medtronic 24-Hour Support

(800) 505-4636